Home › Funds › Siren, L.L.C. › COAG
Siren, L.L.C. position in COAG
Hemab Therapeutics Holdings Inc · Health Care
Siren, L.L.C. reported holding 2,366,235 shares of COAG (Hemab Therapeutics Holdings Inc) in its Q3 2026 13F filing — a position valued at US$73.0M, representing 1.73% of its reported portfolio and ranking #16 among its reported holdings. Siren, L.L.C. has disclosed COAG holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-12 · Source: SEC EDGAR Form 13F-HR
How Siren, L.L.C.'s COAG position evolved
Siren, L.L.C. first disclosed a stake in COAG in Q2 2026 at 2,086,834 shares (US$76.6M). Across 2 filings, Siren, L.L.C. increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 2,366,235 shares valued at US$73.0M — an increase of 279,401 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 2.09M | $76.65M | New |
| Q3 2026 | 2.37M | $72.97M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About COAG and 13F data
COAG (Hemab Therapeutics Holdings Inc) is a Health Care company. 64 other funds we track also report a position in COAG — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$286.8M), Novo Holdings A/S (US$153.6M), Deep Track Capital, LP (US$132.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding COAG
- RA CAPITAL MANAGEMENT, L.P. 7.81M sh · $286.81M · Q2 2026
- Novo Holdings A/S 4.18M sh · $153.55M · Q2 2026
- Deep Track Capital, LP 3.60M sh · $132.30M · Q2 2026
- Avoro Capital Advisors LLC 1.93M sh · $70.71M · Q2 2026
- Bain Capital Life Sciences Investors, LLC 1.65M sh · $60.60M · Q2 2026
- Rock Springs Capital Management LP 575.43K sh · $21.14M · Q2 2026
- Opaleye Management Inc. 47.65K sh · $1.75M · Q2 2026
FAQ
How long has Siren, L.L.C. held COAG?
Siren, L.L.C. has disclosed COAG holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Siren, L.L.C.'s current position in COAG?
As of Q3 2026, Siren, L.L.C. holds 2.37M shares of COAG (Hemab Therapeutics Holdings Inc), valued at $72.97M, representing 1.73% of its reported portfolio and ranking #16.
Has Siren, L.L.C. been buying or selling COAG?
In the latest 13F filing (Q3 2026), Siren, L.L.C. increased its position in COAG.
Which other funds hold COAG?
Other major institutional holders of COAG include RA CAPITAL MANAGEMENT, L.P., Novo Holdings A/S, Deep Track Capital, LP, among 64 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.